For best experience please turn on javascript and use a modern browser!
You are using a browser that is no longer supported by Microsoft. Please upgrade your browser. The site may not present itself correctly if you continue browsing.
Swammerdam Institute for Life Sciences Swammerdam Institute for Life Sciences

Dr C.J. (Caitrín) Crudden

Assistant Professor
Faculty of Science
Swammerdam Institute for Life Sciences
Area of expertise: Cancer Research, Cell Signalling, Breast (Cancer) Biology, Organoids
Visiting address
  • Science Park 904
  • Room number: C2.103
Postal address
Contact details
  • Biography

    Caitrín Crudden is an Assistant Professor at the University of Amsterdam, Swammerdam Institute for Life Sciences, where she teaches and preforms research. As a cancer cell biologist, she has a long standing interest in how cells communicate and how this goes wrong in cancer. Her research here at the UvA focuses on improving human breast (cancer) in vitro models (organoids), with which we hope to ultimately enhance the translation of experimental findings to patient care.

    Caitrín obtained an MSc from the University of Manchester (2013), and her PhD from Karolinska Institutet in Stockholm (2018), where she worked on developing new ways to target the insulin-like growth factor receptor (IGF-1R) signal axis in different cancers. She moved to the Amsterdam UMC for a first post-doc to investigate the contribution of small packages released from cells called 'extracellular vesicles' to oncogenic signaling, obtaining a Marie Curie Fellowship from the European Commission. Upon receiving a ZonMw Veni Fellowship (2021), she joined the group of Martine Smit at the Vrije Universiteit, to work on chemokine signaling and its role in breast cancer metastasis.

  • Publications

    2024

    • Di Niro, L., Linders, A. C., Glynn, T., Pegtel, D. M., Siderius, M., Crudden, C., & Smit, M. J. (2024). G protein-coupled receptors: a gateway to targeting oncogenic EVs? Extracellular Vesicles and Circulating Nucleic Acids, 5(2), 233-248. https://doi.org/10.20517/evcna.2024.10

    2023

    • Bebelman, M. P., Setiawan, I. M., Bergkamp, N. D., van Senten, J. R., Crudden, C., Bebelman, J. P. M., Verweij, F. J., van Niel, G., Siderius, M., Pegtel, D. M., & Smit, M. J. (2023). Exosomal release of the virus-encoded chemokine receptor US28 contributes to chemokine scavenging. iScience, 26(8), Article 107412. https://doi.org/10.1016/j.isci.2023.107412
    • Cismas, S., Pasca, S., Crudden, C., Trocoli Drakensjo, I., Suleymanova, N., Zhang, S., Gebhard, B., Song, D., Neo, S., Shibano, T., Smith, T. J., Calin, G. A., Girnita, A., & Girnita, L. (2023). Competing Engagement of β-arrestin Isoforms Balances IGF1R/p53 Signaling and Controls Melanoma Cell Chemotherapeutic Responsiveness. Molecular Cancer Research, 21(12), 1288-1302. https://doi.org/10.1158/1541-7786.MCR-22-0871
    • Song, D., Cismas, S., Crudden, C., Trocme, E., Worrall, C., Suleymanova, N., Lin, T., Zheng, H., Seregard, S., Girnita, A., & Girnita, L. (2023). Correction: IGF-1R is a molecular determinant for response to p53 reactivation therapy in conjunctival melanoma. Oncogene, 42(11), 858. https://doi.org/10.1038/s41388-023-02607-8

    2022

    • Song, D., Cismas, S., Crudden, C., Trocme, E., Worrall, C., Suleymanova, N., Lin, T., Zheng, H., Seregard, S., Girnita, A., & Girnita, L. (2022). IGF-1R is a molecular determinant for response to p53 reactivation therapy in conjunctival melanoma. Oncogene, 41(4), 600-611. https://doi.org/10.1038/s41388-021-02111-x

    2021

    • Bebelman, M. P., Janssen, E., Pegtel, D. M., & Crudden, C. (2021). The forces driving cancer extracellular vesicle secretion. Neoplasia, 23(1), 149-157. https://doi.org/10.1016/j.neo.2020.11.011
    • Crudden, C., Shibano, T., Song, D., Dragomir, M. P., Cismas, S., Serly, J., Nedelcu, D., Fuentes-Mattei, E., Tica, A., Calin, G. A., Girnita, A., & Girnita, L. (2021). Inhibition of G Protein-Coupled Receptor Kinase 2 Promotes Unbiased Downregulation of IGF1 Receptor and Restrains Malignant Cell Growth. Cancer Research, 81(2), 501-514. https://doi.org/10.1158/0008-5472.CAN-20-1662

    2020

    2019

    • Crudden, C., Song, D., Cismas, S., Trocmé, E., Pasca, S., Calin, G. A., Girnita, A., & Girnita, L. (2019). Below the Surface: IGF-1R Therapeutic Targeting and Its Endocytic Journey. Cells, 8(10). https://doi.org/10.3390/cells8101223

    2018

    • Crudden, C., Shibano, T., Song, D., Suleymanova, N., Girnita, A., & Girnita, L. (2018). Blurring Boundaries: Receptor Tyrosine Kinases as functional G Protein-Coupled Receptors. International review of cell and molecular biology, 339, 1-40. https://doi.org/10.1016/bs.ircmb.2018.02.006
    • Lohcharoenkal, W., Das Mahapatra, K., Pasquali, L., Crudden, C., Kular, L., Akkaya Ulum, Y. Z., Zhang, L., Xu Landén, N., Girnita, L., Jagodic, M., Ståhle, M., Sonkoly, E., & Pivarcsi, A. (2018). Genome-Wide Screen for MicroRNAs Reveals a Role for miR-203 in Melanoma Metastasis. Journal of Investigative Dermatology, 138(4), 882-892. https://doi.org/10.1016/j.jid.2017.09.049

    2017

    • Suleymanova, N., Crudden, C., Shibano, T., Worrall, C., Oprea, I., Tica, A., Calin, G. A., Girnita, A., & Girnita, L. (2017). Functional antagonism of β-arrestin isoforms balance IGF-1R expression and signalling with distinct cancer-related biological outcomes. Oncogene, 36(41), 5734-5744. https://doi.org/10.1038/onc.2017.179
    • Suleymanova, N., Crudden, C., Worrall, C., Dricu, A., Girnita, A., & Girnita, L. (2017). Enhanced response of melanoma cells to MEK inhibitors following unbiased IGF-1R down-regulation. Oncotarget, 8(47), 82256-82267. https://doi.org/10.18632/oncotarget.19286
    • Worrall, C., Suleymanova, N., Crudden, C., Trocoli Drakensjö, I., Candrea, E., Nedelcu, D., Takahashi, S. I., Girnita, L., & Girnita, A. (2017). Unbalancing p53/Mdm2/IGF-1R axis by Mdm2 activation restrains the IGF-1-dependent invasive phenotype of skin melanoma. Oncogene, 36(23), 3274-3286. https://doi.org/10.1038/onc.2016.472

    2016

    • Girnita, L., Girnita, A., & Crudden, C. (2016). Differential Regulation of IGF-1 and Insulin Signaling by GRKs. In Methods in Pharmacology and Toxicology (pp. 151-171). (Methods in Pharmacology and Toxicology). Humana Press Inc., 2007. https://doi.org/10.1007/978-1-4939-3798-1_7
    • Girnita, L., Takahashi, S. I., Crudden, C., Fukushima, T., Worrall, C., Furuta, H., Yoshihara, H., Hakuno, F., & Girnita, A. (2016). Chapter Seven - When Phosphorylation Encounters Ubiquitination: A Balanced Perspective on IGF-1R Signaling. In S. K. Shenoy (Ed.), Ubiquitination and Transmembrane Signaling (pp. 277-311). (Progress in Molecular Biology and Translational Science; Vol. 141). Elsevier B.V. https://doi.org/10.1016/bs.pmbts.2016.04.001

    2015

    • Crudden, C., Girnita, A., & Girnita, L. (2015). Targeting the IGF-1R: The Tale of the Tortoise and the Hare. Frontiers in Endocrinology, 6, 64. https://doi.org/10.3389/fendo.2015.00064
    • Crudden, C., Ilic, M., Suleymanova, N., Worrall, C., Girnita, A., & Girnita, L. (2015). The dichotomy of the Insulin-like growth factor 1 receptor: RTK and GPCR: friend or foe for cancer treatment? Growth Hormone & IGF Research, 25(1), 2-12. https://doi.org/10.1016/j.ghir.2014.10.002

    Prize / grant

    • Crudden, C. (2022). ZonMw Off-Road Grant.
    • Crudden, C. (2021). ZonMw Veni Fellowship; 09150162010212.
    • Crudden, C. (2018). Marie Skłodowska-Curie Fellowship; 845391.
    This list of publications is extracted from the UvA-Current Research Information System. Questions? Ask the library or the Pure staff of your faculty / institute. Log in to Pure to edit your publications. Log in to Personal Page Publication Selection tool to manage the visibility of your publications on this list.
  • Ancillary activities
    No ancillary activities
edit contact information   edit profile page